Casdin Capital, LLC - Q2 2022 holdings

$1.18 Billion is the total value of Casdin Capital, LLC's 40 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 36.2% .

 Value Shares↓ Weighting
 EQRX INC$185,385,000
+13.6%
39,527,6690.0%15.68%
+114.1%
ALNY SellALNYLAM PHARMACEUTICALS INC$117,409,000
-28.1%
805,000
-19.5%
9.93%
+35.6%
BLFS  BIOLIFE SOLUTIONS INC$104,490,000
-39.2%
7,566,2920.0%8.84%
+14.6%
RLAY BuyRELAY THERAPEUTICS INC$68,149,000
-41.0%
4,068,574
+5.5%
5.76%
+11.3%
 MAXCYTE INC$66,084,000
-32.3%
13,971,3340.0%5.59%
+27.6%
BPMC SellBLUEPRINT MEDICINES CORP$58,087,000
-41.3%
1,150,000
-25.8%
4.91%
+10.6%
 SOMALOGIC INC$55,999,000
-43.6%
12,389,0820.0%4.74%
+6.3%
FATE SellFATE THERAPEUTICS INC$52,038,000
-60.5%
2,100,000
-38.2%
4.40%
-25.6%
SRPT SellSAREPTA THERAPEUTICS INC$48,724,000
-22.0%
650,000
-18.8%
4.12%
+47.0%
VERV  VERVE THERAPEUTICS INC$47,951,000
-33.0%
3,138,1670.0%4.05%
+26.3%
RVMD  REVOLUTION MEDICINES INC$46,191,000
-23.6%
2,370,0000.0%3.91%
+44.1%
DNLI  DENALI THERAPEUTICS INC$44,145,000
-8.5%
1,500,0000.0%3.73%
+72.5%
IPSC  CENTURY THERAPEUTICS INC$26,934,000
-33.3%
3,206,3800.0%2.28%
+25.8%
 ABSCI CORPORATION$25,626,000
-60.6%
7,718,5930.0%2.17%
-25.7%
GBT SellGLOBAL BLOOD THERAPEUTICS IN$25,560,000
-44.3%
800,000
-39.6%
2.16%
+5.0%
BuySEMA4 HOLDINGS CORP$20,711,000
+34.9%
16,437,500
+228.8%
1.75%
+154.5%
 TENAYA THERAPEUTICS INC$20,194,000
-52.2%
3,586,8180.0%1.71%
-9.9%
EXAS SellEXACT SCIENCES CORP$17,726,000
-80.9%
450,000
-66.2%
1.50%
-64.1%
TWST SellTWIST BIOSCIENCE CORP$17,480,000
-59.8%
500,000
-43.2%
1.48%
-24.1%
AGIO SellAGIOS PHARMACEUTICALS INC$17,403,000
-71.4%
785,000
-62.4%
1.47%
-46.1%
SellTANGO THERAPEUTICS INC$15,855,000
-61.9%
3,500,000
-36.2%
1.34%
-28.1%
BEAM SellBEAM THERAPEUTICS INC$14,516,000
-69.1%
375,000
-54.2%
1.23%
-41.7%
GH SellGUARDANT HEALTH INC$10,993,000
-60.5%
272,500
-35.1%
0.93%
-25.5%
KRTX NewKARUNA THERAPEUTICS INC$10,753,00085,000
+100.0%
0.91%
 2SEVENTY BIO INC$8,115,000
-22.6%
614,7540.0%0.69%
+46.0%
ABCL NewABCELLERA BIOLOGICS INC$7,988,000750,000
+100.0%
0.68%
SellEXSCIENTIA PLCads$7,230,000
-29.7%
663,900
-7.0%
0.61%
+32.5%
MRTX SellMIRATI THERAPEUTICS INC$6,512,000
-22.7%
97,000
-5.4%
0.55%
+45.8%
GLUE SellMONTE ROSA THERAPEUTICS INC$4,940,000
-63.3%
510,882
-46.8%
0.42%
-30.8%
CLDX NewCELLDEX THERAPEUTICS INC NEW$4,448,000165,000
+100.0%
0.38%
PMVP NewPMV PHARMACEUTICALS INC$4,275,000300,000
+100.0%
0.36%
SGMO NewSANGAMO THERAPEUTICS INC$4,140,0001,000,000
+100.0%
0.35%
FDMT  4D MOLECULAR THERAPEUTICS IN$3,877,000
-53.8%
555,4550.0%0.33%
-13.0%
OMIC SellSINGULAR GENOMICS SYSTEMS IN$3,307,000
-63.7%
865,722
-40.0%
0.28%
-31.4%
MGTA SellMAGENTA THERAPEUTICS INC$2,898,000
-64.0%
2,415,000
-12.9%
0.24%
-32.1%
ORIC  ORIC PHARMACEUTICALS INC$2,695,000
-16.1%
601,5150.0%0.23%
+58.3%
NVTA SellINVITAE CORP$2,534,000
-97.4%
1,038,388
-91.5%
0.21%
-95.1%
SellSCIENCE 37 HOLDINGS INC$452,000
-95.3%
225,000
-87.5%
0.04%
-91.2%
 LIANBIOsponsored ads$446,000
-41.8%
206,4150.0%0.04%
+11.8%
KRON SellKRONOS BIO INC$451,000
-89.3%
123,839
-78.8%
0.04%
-79.9%
DBTX ExitDECIBEL THERAPEUTICS INC$0-330,000
-100.0%
-0.04%
RXRX ExitRECURSION PHARMACEUTICALS INcl a$0-548,156
-100.0%
-0.18%
CDXS ExitCODEXIS INC$0-300,000
-100.0%
-0.28%
ZLAB ExitZAI LAB LTDadr$0-150,000
-100.0%
-0.30%
GBIO ExitGENERATION BIO CO$0-1,324,275
-100.0%
-0.44%
SEER ExitSEER INC$0-800,000
-100.0%
-0.55%
ADPT ExitADAPTIVE BIOTECHNOLOGIES COR$0-1,000,000
-100.0%
-0.62%
ExitGINKGO BIOWORKS HOLDINGS INC$0-4,202,808
-100.0%
-0.76%
ExitDERMTECH INC$0-1,745,000
-100.0%
-1.15%
BGNE ExitBEIGENE LTDsponsored adr$0-150,000
-100.0%
-1.27%
CDNA ExitCAREDX INC$0-1,153,335
-100.0%
-1.91%
PACB ExitPACIFIC BIOSCIENCES CALIF IN$0-7,990,652
-100.0%
-3.26%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-08-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BLUEPRINT MEDICINES CORP32Q3 20239.6%
ALNYLAM PHARMACEUTICALS INC32Q3 20239.9%
AGIOS PHARMACEUTICALS INC27Q2 202212.1%
GLOBAL BLOOD THERAPEUTICS IN27Q2 20227.1%
FATE THERAPEUTICS INC26Q3 20238.3%
BIOLIFE SOLUTIONS INC22Q3 202314.9%
CODEXIS INC22Q3 20238.1%
SAREPTA THERAPEUTICS INC21Q3 202313.6%
BLUEBIRD BIO INC21Q4 20207.8%
ILLUMINA INC21Q3 20236.0%

View Casdin Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Casdin Capital, LLC Q2 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Absci CorpMay 08, 20234,448,2604.8%
CODEXIS, INC.Sold outFebruary 14, 202300.0%
DermTech, Inc.Sold outFebruary 14, 202300.0%
Invitae CorpFebruary 14, 20239,038,3883.7%
Magenta Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Tango Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Verve Therapeutics, Inc.February 14, 20232,290,5713.7%
Tenaya Therapeutics, Inc.December 07, 20226,427,2009.9%
Fulcrum Therapeutics, Inc.February 11, 20211,241,1764.5%
Gritstone Oncology, Inc.Sold outFebruary 11, 202100.0%

View Casdin Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-18
SC 13D/A2024-04-08
42024-03-28
32024-03-25
42024-03-25
42024-03-20
SC 13D/A2024-03-20
42024-03-06
42024-03-06
13F-HR2024-02-14

View Casdin Capital, LLC's complete filings history.

Compare quarters

Export Casdin Capital, LLC's holdings